Eli Lilly & Co. (LLY) Announces Favorable CHMP Opinion for Ixekizumab for Treatment of Moderate-to-Severe Plaque Psoriasis
Tweet Send to a Friend
Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
